MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document

MiMedx reiterates Fourth Quarter and Full Year 2017 Guidance MARIETTA, Ga., Nov. 17, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and th... Regenerative Medicine, FDA MiMedx, EpiFix, Venous Leg Ulcer, Diabetic Foot Ulcer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news